9th Circ. Denies Rehearing In CTI Contract Suit

Law360, New York (January 8, 2010, 4:18 PM EST) -- A federal appeals court won't budge on its finding that Cell Therapeutics Inc.’s settlement of a qui tam suit should not preclude CTI from seeking contractual indemnification from its reimbursement consultant, a predecessor of Lash Group Inc., for damages as part of the government’s investigation of its leukemia treatment Trisonex.

The U.S. Court of Appeals for the Ninth Circuit on Wednesday denied a petition for panel rehearing and rehearing en banc, requested by Lash, and said no further petitions would be entertained.

The Ninth Circuit revised...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.